Role of tyrosine kinase inhibitors in the management of philadelphia chromosome-positive acute lymphoblastic leukemia

Michael S. Mathisen, Susan O'Brien, Deborah Thomas, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutively active kinase involved in cell signaling and survival. When managed with multiagent chemotherapy regimens alone, patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome- negative. Small-molecule tyrosine kinase inhibitors, such as imatinib and dasatinib, directly inhibit the BCR-ABL kinase, offering a targeted approach as a therapeutic option. As a result of several clinical trials with adequate follow-up, imatinib combined with chemotherapy represents the current standard of care for patients with newly diagnosed disease. Allogeneic stem cell transplantation has previously been the only modality to offer the potential for a cure, and it still should be considered for all patients deemed able to tolerate such an intervention. Second-generation tyrosine kinase inhibitors, such as dasatinib, may further improve the outcome in these patients. The role of molecular monitoring and the use of tyrosine kinase inhibitors after stem cell transplantation are areas of active investigation, and the results of ongoing trials will help to clarify the optimal management of these patients.

Original languageEnglish (US)
Pages (from-to)187-194
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Volume6
Issue number3
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein-Tyrosine Kinases
Stem Cell Transplantation
Phosphotransferases
Drug Therapy
Standard of Care
Chromosome Aberrations
Cell Survival
Clinical Trials
Survival

Keywords

  • Acute lymphoblastic leukemia
  • ALL
  • Chemotherapy
  • Complications
  • Dasatinib
  • Imatinib
  • Ph+ ALL
  • Philadelphia chromosome
  • Stem cell transplantation
  • Therapy
  • Treatment
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Role of tyrosine kinase inhibitors in the management of philadelphia chromosome-positive acute lymphoblastic leukemia. / Mathisen, Michael S.; O'Brien, Susan; Thomas, Deborah; Cortes, Jorge; Kantarjian, Hagop; Ravandi, Farhad.

In: Current Hematologic Malignancy Reports, Vol. 6, No. 3, 01.09.2011, p. 187-194.

Research output: Contribution to journalArticle

Mathisen, Michael S. ; O'Brien, Susan ; Thomas, Deborah ; Cortes, Jorge ; Kantarjian, Hagop ; Ravandi, Farhad. / Role of tyrosine kinase inhibitors in the management of philadelphia chromosome-positive acute lymphoblastic leukemia. In: Current Hematologic Malignancy Reports. 2011 ; Vol. 6, No. 3. pp. 187-194.
@article{c46dd68c512b49e5bcc7af0c77d09e1c,
title = "Role of tyrosine kinase inhibitors in the management of philadelphia chromosome-positive acute lymphoblastic leukemia",
abstract = "The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutively active kinase involved in cell signaling and survival. When managed with multiagent chemotherapy regimens alone, patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome- negative. Small-molecule tyrosine kinase inhibitors, such as imatinib and dasatinib, directly inhibit the BCR-ABL kinase, offering a targeted approach as a therapeutic option. As a result of several clinical trials with adequate follow-up, imatinib combined with chemotherapy represents the current standard of care for patients with newly diagnosed disease. Allogeneic stem cell transplantation has previously been the only modality to offer the potential for a cure, and it still should be considered for all patients deemed able to tolerate such an intervention. Second-generation tyrosine kinase inhibitors, such as dasatinib, may further improve the outcome in these patients. The role of molecular monitoring and the use of tyrosine kinase inhibitors after stem cell transplantation are areas of active investigation, and the results of ongoing trials will help to clarify the optimal management of these patients.",
keywords = "Acute lymphoblastic leukemia, ALL, Chemotherapy, Complications, Dasatinib, Imatinib, Ph+ ALL, Philadelphia chromosome, Stem cell transplantation, Therapy, Treatment, Tyrosine kinase inhibitors",
author = "Mathisen, {Michael S.} and Susan O'Brien and Deborah Thomas and Jorge Cortes and Hagop Kantarjian and Farhad Ravandi",
year = "2011",
month = "9",
day = "1",
doi = "10.1007/s11899-011-0093-y",
language = "English (US)",
volume = "6",
pages = "187--194",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Role of tyrosine kinase inhibitors in the management of philadelphia chromosome-positive acute lymphoblastic leukemia

AU - Mathisen, Michael S.

AU - O'Brien, Susan

AU - Thomas, Deborah

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutively active kinase involved in cell signaling and survival. When managed with multiagent chemotherapy regimens alone, patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome- negative. Small-molecule tyrosine kinase inhibitors, such as imatinib and dasatinib, directly inhibit the BCR-ABL kinase, offering a targeted approach as a therapeutic option. As a result of several clinical trials with adequate follow-up, imatinib combined with chemotherapy represents the current standard of care for patients with newly diagnosed disease. Allogeneic stem cell transplantation has previously been the only modality to offer the potential for a cure, and it still should be considered for all patients deemed able to tolerate such an intervention. Second-generation tyrosine kinase inhibitors, such as dasatinib, may further improve the outcome in these patients. The role of molecular monitoring and the use of tyrosine kinase inhibitors after stem cell transplantation are areas of active investigation, and the results of ongoing trials will help to clarify the optimal management of these patients.

AB - The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutively active kinase involved in cell signaling and survival. When managed with multiagent chemotherapy regimens alone, patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome- negative. Small-molecule tyrosine kinase inhibitors, such as imatinib and dasatinib, directly inhibit the BCR-ABL kinase, offering a targeted approach as a therapeutic option. As a result of several clinical trials with adequate follow-up, imatinib combined with chemotherapy represents the current standard of care for patients with newly diagnosed disease. Allogeneic stem cell transplantation has previously been the only modality to offer the potential for a cure, and it still should be considered for all patients deemed able to tolerate such an intervention. Second-generation tyrosine kinase inhibitors, such as dasatinib, may further improve the outcome in these patients. The role of molecular monitoring and the use of tyrosine kinase inhibitors after stem cell transplantation are areas of active investigation, and the results of ongoing trials will help to clarify the optimal management of these patients.

KW - Acute lymphoblastic leukemia

KW - ALL

KW - Chemotherapy

KW - Complications

KW - Dasatinib

KW - Imatinib

KW - Ph+ ALL

KW - Philadelphia chromosome

KW - Stem cell transplantation

KW - Therapy

KW - Treatment

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=80055063164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055063164&partnerID=8YFLogxK

U2 - 10.1007/s11899-011-0093-y

DO - 10.1007/s11899-011-0093-y

M3 - Article

C2 - 21660654

AN - SCOPUS:80055063164

VL - 6

SP - 187

EP - 194

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 3

ER -